Skip to main content
. 2019 Feb;31(1):1–28. doi: 10.21147/j.issn.1000-9604.2019.01.01

4.

Anti-angiogenic drugs and targeted therapies for NSCLC

Regimen Dose Time
Anti-angiogenic drugs
 Endostatin 7.5 mg/m2 d1−d14, 21 d/cycle
 Bevacizumab 7.5−15 mg/kg d1, 21 d/cycle
Targeted therapies
 Gefitinib 250 mg Qd
 Erlotinib 150 mg Qd
 Icotinib 125 mg Tid
 Alfatinib 40 mg Qd
 Crizotinib 250 mg Bid